pamidronate has been researched along with Connective Tissue Diseases in 2 studies
Connective Tissue Diseases: A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erbaş, İM | 1 |
| İlgün Gürel, D | 1 |
| Manav Kabayeğit, Z | 1 |
| Koç, A | 1 |
| Ünüvar, T | 1 |
| Abacı, A | 1 |
| Böber, E | 1 |
| Anık, A | 1 |
| Nzeusseu Toukap, A | 1 |
| Depresseux, G | 1 |
| Devogelaer, JP | 1 |
| Houssiau, FA | 1 |
1 trial available for pamidronate and Connective Tissue Diseases
| Article | Year |
|---|---|
Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Bone Density; Bone Remodeling; Connective Tis | 2005 |
1 other study available for pamidronate and Connective Tissue Diseases
| Article | Year |
|---|---|
Clinical, genetic characteristics and treatment outcomes of children and adolescents with osteogenesis imperfecta: a two-center experience.
Topics: Adolescent; Child; Child, Preschool; Collagen Type I; Connective Tissue Diseases; Female; Fractures, | 2022 |